Regarding eotaxin-1, similar findings have been suggested in two previous reports that showed an increase in serum levels of eotaxin-1 and eotaxin-2 in patients with asthma following benralizumab (100 mg or 200 mg) treatment for 8 weeks or benralizumab (200 mg) treatment for 52 weeks [31,32]. This evidence concerns the gene CCL11 and asthma.